Dr. David Y Oh, MD, PhD
Claim this profileUniversity of California, San Francisco
Studies Prostate Cancer
Studies Prostate Adenocarcinoma
3 reported clinical trials
10 drugs studied
Affiliated Hospitals
Clinical Trials David Y Oh, MD, PhD is currently running
Atezolizumab-Based Combination Therapy
for Prostate Cancer
This phase II trial studies how well atezolizumab works alone or in combination with etrumadenant or tocilizumab in treating men with localized prostate cancer before radical prostatectomy. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Androgens can cause the growth of prostate cancer cells. IL-6 is expressed by prostate cancer and within the tumor microenvironment and shown to enhance prostate cancer and disease progression. Treatment with an anti-IL-6 antibody such as tocilizumab may inhibit cancer progression. Giving atezolizumab in combination with etrumadenant or tocilizumab may work better in treating prostate cancer.
Recruiting1 award Phase 213 criteria
Pembrolizumab +/− Axitinib
for Renal Cell Carcinoma
This phase II trial studies how well pembrolizumab with or without standard of care axitinib works in treating patients with clear cell kidney cancer that has spread to nearby tissues or lymph nodes (locally advanced) or other places in the body (metastatic) who are undergoing surgery. Pembrolizumab is an antibody that is designed to bind to and block the activity of PD-1, a molecule in the body that may be responsible for inhibiting the body's immune response against cancer cells. Axitinib is a type of drug known as a tyrosine kinase inhibitor. Tyrosine kinase inhibitors work by blocking enzymes called tyrosine kinases. These enzymes may be too active or found at high levels in some types of cancer cells and blocking them may help keep cancer cells from growing. Giving pembrolizumab with or without axitinib may work better in controlling the cancer and decrease the likelihood of it coming back following surgery in patients with kidney cancer compared to usual treatment (surgery followed by chemotherapy and/or radiation therapy).
Recruiting1 award Phase 211 criteria
More about David Y Oh, MD, PhD
Clinical Trial Related5 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments David Y Oh, MD, PhD has experience with
- Pembrolizumab
- Atezolizumab
- Etrumadenant
- Tocilizumab
- Leuprolide Acetate
- Prednisone
Breakdown of trials David Y Oh, MD, PhD has run
Prostate Cancer
Prostate Adenocarcinoma
Kidney Cancer
Renal Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does David Y Oh, MD, PhD specialize in?
David Y Oh, MD, PhD focuses on Prostate Cancer and Prostate Adenocarcinoma. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are undergoing treatment.
Is David Y Oh, MD, PhD currently recruiting for clinical trials?
Yes, David Y Oh, MD, PhD is currently recruiting for 2 clinical trials in San Francisco California. If you're interested in participating, you should apply.
Are there any treatments that David Y Oh, MD, PhD has studied deeply?
Yes, David Y Oh, MD, PhD has studied treatments such as Pembrolizumab, Atezolizumab, Etrumadenant.
What is the best way to schedule an appointment with David Y Oh, MD, PhD?
Apply for one of the trials that David Y Oh, MD, PhD is conducting.
What is the office address of David Y Oh, MD, PhD?
The office of David Y Oh, MD, PhD is located at: University of California, San Francisco, San Francisco, California 94143 United States. This is the address for their practice at the University of California, San Francisco.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.